Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Wilms' Tumour article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Wilms' tumours are the most common intra-abdominal tumours of childhood. A Wilms' tumour is an undifferentiated mesodermal tumour of the intermediate cell mass (primitive renal tubules and mesenchymal cells). It may be sporadic or familial.
- Wilms' tumour is the most common renal tumour of childhood and affects about 1 in 10,000 children.
- The incidence is estimated at 7 in 1,000,000 children under 16 years of age.
- Wilms' tumour is the second most common intra-abdominal cancer of childhood and the fifth most common paediatric malignancy overall (approximately 6% of all paediatric cancers).
- Only 3% of Wilms' tumours are reported in adults. Most adult patients are diagnosed unexpectedly following nephrectomy for presumed renal cell carcinoma.
- In 5-10% of patients, both kidneys are affected at the same time (synchronous bilateral Wilms' tumour) or one after the other (metachronous bilateral Wilms' tumour).
Wilms' tumours usually develop in otherwise healthy children but approximately 10% occur in children with recognised malformations; either:
- 'Overgrowth syndromes' (excessive prenatal and postnatal somatic growth resulting in macroglossia, nephromegaly and hemihypertrophy) - most commonly, Beckwith-Wiedemann syndrome or isolated hemihypertrophy. Others include Perlman syndrome, Sotos' syndrome, and Simpson-Golabi-Behmel syndrome.
- No 'overgrowth' - associated with Edwards syndrome (trisomy 18), Bloom's syndrome, Denys-Drash syndrome; or WAGR (Wilms' with Aniridia, Gonadoblastoma (genitourinary malformations), and Retardation).
Familial Wilms' tumour
Hereditary Wilms' tumour (either bilateral tumours or a family history of the neoplasm) is uncommon. Several different families with Wilms' tumours have been identified. All are transmitted in an autosomal dominant manner, caused by mutations in one of at least three genes:
- One related to the WT1 gene on chromosome 11 (11p13) - (includes those patients with WAGR) - encodes a protein which is a transcriptional repressor downregulating IGF-II, an insulin-like growth factor.
- Other families (including those with Beckwith-Wiedemann syndrome) have a different mutation - of the WT2 gene on chromosome 11 (11p15.5).
- Other gene mutations, thought to be on chromosome 16 (WT3-16q) and/or chromosome 1p can also cause the tumour.
Usually presents in the first five years of life but 3% of presentations are in adults.
95% are unilateral. Only 1-2% have a positive family history.
- The most common presentation is an asymptomatic abdominal mass.
- Abdominal pain.
- Urinary tract infection.
- Hypertension, gross haematuria and fever may occur but are uncommon.
- Advanced disease may rarely present with respiratory symptoms due to lung metastases.
A recommendation for surveillance of children at high risk (familial or associated conditions) included:
- Surveillance should only be offered after review by a clinical geneticist.
- Surveillance should be carried out by renal ultrasound every 3-4 months.
- Surveillance should continue until 5 years of age in all conditions except Beckwith-Wiedemann syndrome, Simpson-Golabi-Behmel syndrome and some familial Wilms' tumour pedigrees, when it should continue until 7 years.
- Useful laboratory tests include FBC, renal function and electrolytes and urinalysis.
- Genetic studies may reveal the chromosomal abnormalities consistent with the condition.
- Ultrasound and/or intravenous pyelogram (IVP) may show distortion of the renal pelvis; hydronephrosis. Dynamic imaging of the renal vein and inferior vena cava may be contributory.
- Renal angiography may help to show a more detailed view of the blood vessels.
- CT and MRI scanning may help to determine the nature of the tumour and may also reveal the degree of involvement of the lymph nodes, whether the other kidney is involved and invasion into blood vessels or the liver.
- Transcutaneous renal biopsy should be avoided, as this may make the condition worse.
- Chest CT to detect lung metastases.
|Staging of Wilms' tumour|
|Stage I||Tumour limited to the kidney and completely excised. Renal capsule is intact.|
The tumour is not ruptured before or during removal.
The vessels of the renal sinus are not involved.
There is no residual tumour apparent beyond the margins of excision.
|Stage II||Tumour extends beyond the kidney but is completely excised. No residual tumour is apparent at or beyond the margins of excision.|
There may be:
|Stage III||There is residual tumour confined to the abdomen. There may be one or more of the following: |
|Stage IV||Haematogenous metastases - beyond stage III - eg, to the lung, liver, bone, or brain.|
|Stage V||Bilateral renal involvement at initial diagnosis. Attempt to stage each side according to the above criteria on the basis of extent of disease prior to biopsy.|
Four-year survival was 94% for those patients whose most advanced lesion was stage I-II; 76% where it was stage III.
- For most patients, nephrectomy followed by chemotherapy (regimes include vincristine, dactinomycin and doxorubicin, sometimes with additional cyclophosphamide) can be curative.
- Routine postoperative radiotherapy to the flank is beneficial in patients with a stage III tumour.
- Patients with massive, nonresectable unilateral tumours, bilateral tumours, or venacaval tumour thrombus above the hepatic veins should be considered for pre-operative chemotherapy because of the risk of initial surgical resection.
- With treatment, over 90% of children diagnosed with Wilms' tumour survive long-term.
- Long-term survival is above 75% for those with metastatic disease.
- There is an increased risk of second tumours in survivors of Wilms' tumour. Second tumours include bone and soft tissue sarcomas, breast cancer, lymphoma, gastrointestinal tumours and melanoma. Acute leukaemias may also occur.
Further reading and references
Szychot E, Apps J, Pritchard-Jones K; Wilms' tumor: biology, diagnosis and treatment. Transl Pediatr. 2014 Jan3(1):12-24. doi: 10.3978/j.issn.2224-4336.2014.01.09.
Pietras W; Advances and changes in the treatment of children with nephroblastoma. Adv Clin Exp Med. 2012 Nov-Dec21(6):809-820.
Davidoff AM; Wilms tumor. Adv Pediatr. 201259(1):247-67. doi: 10.1016/j.yapd.2012.04.001.
Ali EM, Elnashar AT; Adult Wilms' tumor: review of literature. J Oncol Pharm Pract. 2012 Mar18(1):148-51. doi: 10.1177/1078155210396264. Epub 2011 Jan 19.
Segers H, van den Heuvel-Eibrink MM, Pritchard-Jones K, et al; Management of adults with Wilms' tumor: recommendations based on international consensus. Expert Rev Anticancer Ther. 2011 Jul11(7):1105-13. doi: 10.1586/era.11.76.
Wilms Tumor and Other Childhood Kidney Tumors; US National Cancer Institute.
Wilm's Tumor 1, WT1; Online Mendelian Inheritance In Man (OMIM)
Wilms Tumor 3, WT3; Online Mendelian Inheritance in Man (OMIM)
Huszno J, Starzyczny-Slota D, Jaworska M, et al; Adult Wilms' tumor - diagnosis and current therapy. Cent European J Urol. 201366(1):39-44. doi: 10.5173/ceju.2013.01.art12. Epub 2013 Apr 26.
Kraemer KH; Xeroderma Pigmentosum, Gene Reviews, Feb 2014
Scott RH, Walker L, Olsen OE, et al; Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Arch Dis Child. 2006 Dec91(12):995-9. Epub 2006 Jul 20.
Dome JS, Perlman EJ, Graf N; Risk stratification for wilms tumor: current approach and future directions. Am Soc Clin Oncol Educ Book. 2014:215-23. doi: 10.14694/EdBook_AM.2014.34.215.
Levitt G; Renal tumours: long-term outcome. Pediatr Nephrol. 2012 Jun27(6):911-6. doi: 10.1007/s00467-011-1998-3. Epub 2011 Sep 27.
Gleason JM, Lorenzo AJ, Bowlin PR, et al; Innovations in the management of Wilms' tumor. Ther Adv Urol. 2014 Aug6(4):165-76. doi: 10.1177/1756287214528023.